Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

Key facts

Sponsor

University of Michigan

Principal Investigator

Zubin Modi, MD

University of Michigan

Intervention

adalimumab(drug)

Enrollment

7 enrolled

Eligibility

6-80 years · All sexes

Timeline

2019 – 2023

Study locations (4)

• The University of Michigan, Ann Arbor, Michigan, United States
• New York University, New York, New York, United States
• Levine Children's Hospital/Atrium Health, Charlotte, North Carolina, United States
• Cleveland Clinic Foundation, Cleveland, Ohio, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Nephrotic syndrome without extrarenal manifestations

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT07267026
  A Study to Evaluate the Safety, Tolerability and PK of SK-09
  Consun Pharmaceutical Group
• RECRUITINGPHASE4NCT07219121
  Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
  Travere Therapeutics, Inc.
• RECRUITINGNANCT06867471
  Effects of Exogenous Ketosis on Proteinuria and Renal Function
  Gødstrup Hospital
• RECRUITINGPHASE3NCT05716880
  Ketoanalogues for Muscle Mass Loss in Nephrotic Syndrome
  Military Institute od Medicine National Research Institute
• RECRUITINGPHASE2NCT05003986
  Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
  Travere Therapeutics, Inc.
• RECRUITINGNCT01209000
  Nephrotic Syndrome Study Network
  University of Michigan
• RECRUITINGNCT01094327
  Proteinuria in Pre and Post Transplant
  University of Miami

See all trials for Nephrotic syndrome without extrarenal manifestations →